A composition containing a Dendropanax morbifera LEV. extract, of the present invention, has excellent activities of inhibiting the oxidation of A2E, inhibiting oxidized A2E-induced death of retinal pigmented epithelial cells, and inhibiting the accumulation of drusen, and thus can be used for preventing eye damage. In addition, a composition containing a Dendropanax morbifera LEV. extract, of the present invention, can be developed even into a therapeutic agent for various eye diseases and a health functional food.

A composition containing a Dendropanax morbifera LEV. extract, of the present invention, has excellent activities of inhibiting the oxidation of A2E, inhibiting oxidized A2E-induced death of retinal pigmented epithelial cells, and inhibiting the accumulation of drusen, and thus can be used for preventing eye damage. In addition, a composition containing a Dendropanax morbifera LEV. extract, of the present invention, can be developed even into a therapeutic agent for various eye diseases and a health functional food.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.

Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Compositions and methods for weight loss and improved glucose control using dietary supplements and food products. Specifically, the invention pertains to the utilization of glucagon-like peptide-1 (GLP-1) agonists, inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4), and agents that improve insulin resistance in formulations comprising nutraceuticals, fibers, sweeteners, phytochemicals, botanical extracts, proteins, peptides, fatty acids, and other natural compounds. These formulations have demonstrated efficacy in facilitating weight loss, combating obesity, and improving glycemic control. The invention also encompasses various dosage forms for administering these compositions, including powders, granules, liquids, tablets, capsules, gels, and food items.

Compositions and methods for weight loss and improved glucose control using dietary supplements and food products. Specifically, the invention pertains to the utilization of glucagon-like peptide-1 (GLP-1) agonists, inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4), and agents that improve insulin resistance in formulations comprising nutraceuticals, fibers, sweeteners, phytochemicals, botanical extracts, proteins, peptides, fatty acids, and other natural compounds. These formulations have demonstrated efficacy in facilitating weight loss, combating obesity, and improving glycemic control. The invention also encompasses various dosage forms for administering these compositions, including powders, granules, liquids, tablets, capsules, gels, and food items.